Extended Data Fig. 3: Incidence of nausea, vomiting, and diarrhea over time. | Nature Medicine

Extended Data Fig. 3: Incidence of nausea, vomiting, and diarrhea over time.

From: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

Extended Data Fig. 3

The percentage of participants receiving tirzepatide or placebo who reported nausea, vomiting, or diarrhea are presented. Percentages are based on number of participants at risk at specific observation time. Events were classed as mild (shown in green), moderate (shown in orange), or severe (shown in red). MTD, maximum tolerated dose (10 or 15 mg); TZP, tirzepatide.

Back to article page